Robert Cook-Deegan’s Viewers’ Guide To the Super Bowl of Gene Patent Cases 2

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Does Myriad have rights to BRCA2?

The race to find mutations associated with inherited risk of breast cancer started with Mary-Claire King’s announcement of linkage to chromosome 17 in fall 1990. As Kevin Davies documented in his book Breakthrough, it is widely accepted that the team led by Mark Skolnick of the University of Utah and Myriad Genetics won that race to find BRCA1. They cloned and sequenced the gene and identified the first high-risk variants several months ahead of King and other rival groups in the UK, France and the United States. Utah/Myriad filed the first patent applications on BRCA1.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The field of surgical oncology has undergone transformative advancements over the last decade. From refining minimally invasive techniques to leveraging immunotherapy and viral oncolytics, our collective goal remains the same: improving patient outcomes while reducing treatment burden. At City of Hope, we have prioritized accelerating the translation of laboratory discoveries into clinical applications, and nowhere is this more evident than in our work with oncolytic viruses, remote surgery, and the integration of AI in surgical decision-making.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login